Device Trial Radar · NCT07467239
A Prospective Clinical Investigation of DMFI300 for Treating Nasolabial Folds
Last checked: Nov 20, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Mar 2, 2026
Primary completion
Mar 31, 2027
Study completion May 31, 2027
Sponsor
- Lead sponsor
- Samyang Biopharmaceuticals CorporationNot on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 12, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, randomized, controlled clinical investigation designed to evaluate the performance and safety of DMFI300 for the treatment of nasolabial folds. 30 adult participants will receive treatment with the investigational device and the comparator device using a split-face design. The study will assess wrinkle severity using validated aesthetic evaluation scales, as well as overall safety.
Conditions
- Nasolabial Folds, Wrinkles
Interventions
DMFI300Device
Injection of DMFI300 for nasolabial folds.
Ellansé-MDevice
Injection of Ellansé-M for nasolabial folds.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Wrinkle Severity Rating Scale (WSRS) as Assessed by the Evaluating Investigator (EI)Time frame: Baseline to Month 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ocean Clinic
Marbella, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.